Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20160730 | 0.94 | ESR1 (0.35) | ESR1RAPGEF4CYP1A2CYP2C19 | |
| SCHEMBL850793 | 0.78 | ESR1 (0.30) | ESR1 | |
| SCHEMBL19198539 | 0.78 | HDAC1 (0.31) | TSHRESR1RAPGEF4 | |
| SCHEMBL18619502 | 0.78 | ESR1 (0.30) | ESR1 | |
| SCHEMBL12656572 | 0.78 | CD44 (0.42) | CYP3A4MAPK1ESR1RAPGEF4 | |
| SCHEMBL2741245 | 0.78 | ALDH1A1 (0.50) | CYP3A4TSHRMAPK1ESR1CYP1A2 | |
| SCHEMBL19199535 | 0.78 | POLB (0.32) | CYP3A4TSHRMAPK1ESR1BCHE | |
| SCHEMBL10072631 | 0.78 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1CYP1A2 | |
| SCHEMBL21760184 | 0.78 | ESR1 (0.30) | ESR1 | |
| SCHEMBL10072636 | 0.78 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ESR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393924-A1 | IMIDAZO [1,2-A] PYRAZINE OR PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVE AND USE THEREOF | Tencent Technology (Shenzhen) Company Limited (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2022087475-A1 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | CYP3A4 3077/4885TSHR 994/4885MAPK1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.